awmsg logo



cetuximab (Erbitux®)


Reference No. 2407

Publication date:
05/01/2016


Appraisal information

cetuximab (Erbitux®) 5 mg/ml solution for infusion


Company: Merck Serono Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 09/09/2015
AWMSG meeting date: 09/12/2015
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 4315
Ministerial ratification: 30/12/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Cetuximab (Erbitux®) is recommended as an option for restricted use within NHS Wales for the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in combination with irinotecan-based chemotherapy or in combination with FOLFOX. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised. Cetuximab (Erbitux®) is not recommended for use within NHS Wales for the treatment of patients with EGFR-expressing, RAS wild-type metastatic colorectal cancer as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download